Investment Rating - The report initiates coverage with a "Buy" rating for the company [12]. Core Viewpoints - The company is a core asset of AECC and has established a comprehensive industrial chain covering various aviation component categories, demonstrating strong competitive advantages in both domestic and international markets [4][10]. - The company has a significant growth potential in the domestic market driven by military aircraft upgrades and maintenance demands, with a projected market space of approximately 792 billion yuan for aviation engine components over the next five years [8][51]. - The company has maintained strong customer loyalty through over 20 years of collaboration with leading international aerospace firms, positioning itself for stable growth in its foreign trade business [8][62]. - The company is strategically positioned to benefit from the domestic production of commercial aircraft engines, particularly in the reverse thrust nacelle systems, which are critical components of the propulsion system [9][10]. Summary by Sections Company Overview - The company is a key player in the aviation engine and gas turbine component manufacturing sector, with a history dating back to the "First Five-Year Plan" in China [22]. - It has multiple subsidiaries that cover nearly the entire industrial chain, enhancing its ability to supply a full range of aviation components [4][7]. Domestic Market Potential - The domestic military aircraft market is expected to provide long-term growth opportunities due to ongoing upgrades and new deployments [8][49]. - The aviation engine is classified as a high-value consumable, creating a sustained demand for replacement and maintenance services [49]. International Market Dynamics - The company has established high barriers to entry in the international market, with a lengthy qualification process for international commercial aviation engine customers [56][59]. - The foreign trade business has shown robust growth, with revenues increasing from 0.63 billion yuan to 15.19 billion yuan over 17 years, reflecting a compound annual growth rate (CAGR) of 21% [62]. Financial Projections - The company is expected to achieve net profits of 0.92 billion yuan, 1.47 billion yuan, and 2.29 billion yuan for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 34.0%, 59.8%, and 55.3% [10]. Key Competitive Advantages - The company possesses advanced manufacturing capabilities and technologies, including high-efficiency adaptive processing and fatigue resistance techniques, which are essential for producing high-performance aviation components [28][31]. - The subsidiary, AECC Harbin Bearing, is the only aviation bearing product platform under AECC, highlighting its unique asset value in the market [62].

Investment Rating - The report initiates coverage with a "Buy" rating for the company [9]. Core Viewpoints - The company is a core asset of China Aviation Engine Corporation (AECC) and has established a comprehensive industrial chain covering various aviation component categories. It has a strong competitive edge in the manufacturing of aviation engine parts, particularly in domestic and international markets [2][6]. - The company is expected to benefit from the domestic market's shift towards self-sufficiency in aviation engines, particularly in the context of large aircraft development, which presents significant market opportunities for domestic replacements [8][9]. - The company has a robust long-term growth outlook, driven by both domestic demand for military aircraft upgrades and international trade relationships that have been cultivated over two decades [7][9]. Summary by Sections Company Overview - The company is a key player in the aviation engine parts sector, with multiple subsidiaries that cover nearly the entire industrial chain. It specializes in components such as blades, casings, and sheet metal parts, and has a unique position as the only aviation bearing platform under AECC [2][6][19]. Domestic Market Potential - The domestic military aircraft market is expected to drive long-term growth for the company, with an estimated market space of approximately 792 billion yuan for aviation engine components over the next five years. The company is well-positioned to capitalize on the ongoing upgrades and maintenance needs of existing aircraft [7][52]. International Market Dynamics - The company has established strong customer loyalty through over 20 years of collaboration with leading international aviation firms, which is expected to support stable growth in its international business. The barriers to entry in this market are high, ensuring a competitive advantage [7][9][60]. Financial Projections - The company is projected to achieve significant profit growth, with net profits expected to reach 0.92 billion yuan in 2025, 1.47 billion yuan in 2026, and 2.29 billion yuan in 2027, reflecting year-on-year growth rates of 34.0%, 59.8%, and 55.3% respectively [9].

Investment Rating - The investment rating for the company is "Buy" (maintained) [7] Core Views - The company is focusing on chronic diseases, tumors, and immunology, covering four major business segments: pharmaceutical manufacturing, pharmaceutical commerce, medical aesthetics, and industrial microbiology. It is continuously optimizing its product structure and transitioning from generics to innovation. The core products of its subsidiary, China Medical East, are maintaining stable market growth and increasing market share. The medical aesthetics segment is showing growth potential, and the innovative pipeline is entering a harvest period. The projected net profits for 2025-2027 are estimated at 40.61 billion, 47.16 billion, and 55.37 billion yuan, with corresponding EPS of 2.32, 2.69, and 3.16 yuan, leading to PE ratios of 16.3, 14.0, and 11.9 times, respectively [7][8][10]. Summary by Sections Company Overview - The company, established in 1993 and listed in 1999, has developed into a large comprehensive pharmaceutical company covering the entire pharmaceutical industry chain. It has transitioned towards a research and innovation-driven pharmaceutical enterprise since 2018 [18]. Business Performance - The company reported a revenue of 419.1 billion yuan in 2024, a year-on-year increase of 3.2%, and a net profit of 35.1 billion yuan, up 23.7% year-on-year. The pharmaceutical manufacturing segment generated 138.1 billion yuan in revenue, growing by 13.1%, while the medical aesthetics segment saw a slight decline in revenue [8][22]. Innovative Pipeline - The company is focusing on three core areas: oncology, endocrinology, and autoimmune diseases, with a differentiated layout in ADC and PROTAC technologies. The innovative pipeline includes over 80 projects, with several products entering clinical stages. The company is also actively pursuing collaborations and acquisitions to enhance its product offerings [9][39][55]. Financial Summary - The company’s financial metrics show steady growth, with projected revenues of 44.68 billion, 47.95 billion, and 51.83 billion yuan for 2025, 2026, and 2027, respectively. The gross margin is expected to improve from 33.6% in 2025 to 35.4% in 2027, while the net profit margin is projected to increase from 9.1% to 10.7% over the same period [10][28].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% compared to the benchmark index within the next six months [6][13]. Core Views - The company plans to spin off its gold subsidiary, Zijin Gold International, for a listing on the Hong Kong Stock Exchange, which is expected to lead to a revaluation of its assets [3][4]. - The spin-off will involve the integration of multiple overseas gold mining assets, enhancing the company's global footprint and resource base [4]. - The company has launched an employee stock ownership plan, reflecting management's confidence in future growth [5]. Financial Summary - The latest closing price is 17.82 yuan, with a total market capitalization of 473.6 billion yuan [2]. - The company expects net profits for 2025-2027 to be 40.57 billion, 44.04 billion, and 50.01 billion yuan respectively, with year-over-year growth rates of 26.57%, 8.58%, and 13.54% [6][9]. - The projected earnings per share (EPS) for 2025-2027 are 1.53, 1.66, and 1.88 yuan, with corresponding price-to-earnings (P/E) ratios of 11.68, 10.75, and 9.47 [9][12].

证券研究报告 | 首次覆盖报告 gszqdatemark 2025 06 02 年 月 日 兴业银锡（000426.SZ） 手握多座世界级矿山，银锡龙头未来可期 立足银、锡、锌，公司资源版图由内蒙走向全球。公司上市以来经历了 2011、2014-2016、2023-至今三轮矿山资源扩充。立足银、锌、锡资源压 舱石，目前旗下银漫、乾金达、融冠已具备三座亿级利润的大型矿山，成 为支撑公司高成长的现金奶牛。2023 年起，公司陆续完成了博盛矿业（黄 金）、宇邦矿业（（银锌锌）收购，托管大股东旗下布敦银根矿业（银锌锌）， 拟要约收购大西洋锡业（锡），完成新一轮资源版图扩充。 手握三座世界级银矿，扬帆起航正当时。目前子公司银漫矿业拥有白银资 源量 8058 吨，平均品位 185g/吨；宇邦矿业保有白银资源量 1.79 万吨， 平均品位 125g/吨，单体银矿储量排名位列亚洲第一，全球第五；托管大 股东的布敦银根矿业拥有白银资源量 1.1 万吨，平均品位 158g/吨。根据 世界白银协会披露的全球前十大在产矿山，剔除第一大 KGHM 后（资源量 8.3 万吨，平均品位 58.3g/吨）平均资源量 7100 吨，平均品位 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [7] Core Views - The company is focusing on chronic diseases, tumors, and immunology, covering four major business segments: pharmaceutical manufacturing, pharmaceutical commerce, medical aesthetics, and industrial microbiology. It is continuously optimizing its product structure and transitioning from generics to innovation. The core products of its subsidiary, China Medical East, are maintaining stable market sales and increasing market share. The medical aesthetics segment is showing growth potential, and the innovative pipeline is entering a harvest period. The projected net profit for 2025-2027 is estimated at 40.61 billion, 47.16 billion, and 55.37 billion yuan, with corresponding EPS of 2.32, 2.69, and 3.16 yuan, and PE ratios of 16.3, 14.0, and 11.9 times, respectively [7][8][10]. Summary by Sections Company Overview - The company, established in 1993 and listed in 1999, has developed into a large comprehensive pharmaceutical company covering the entire pharmaceutical industry chain. It has shifted its strategy towards research-driven innovation since 2018, optimizing its product structure and transitioning from generics to innovative products [18]. Business Performance - The company reported a revenue of 419.1 billion yuan in 2024, a year-on-year increase of 3.2%, and a net profit of 35.1 billion yuan, up 23.7% year-on-year. The pharmaceutical manufacturing segment generated 138.1 billion yuan in revenue, growing by 13.1%, while the medical aesthetics segment saw a slight decline in revenue [8][22]. Innovative Pipeline - The company is focusing on three core areas: tumors, endocrinology, and autoimmune diseases, with a differentiated layout in ADC and PROTAC technologies. The innovative pipeline includes over 80 projects, with several products entering clinical stages. The company aims to leverage its innovative capabilities to drive long-term growth [9][39][55]. Financial Summary - The company’s financial metrics show steady growth, with projected revenues of 44.68 billion, 47.95 billion, and 51.83 billion yuan for 2025, 2026, and 2027, respectively. The gross margin is expected to improve from 33.6% in 2025 to 35.4% in 2027, while the net margin is projected to increase from 9.1% to 10.7% over the same period [10][28].

Investment Rating - The report maintains a "Buy" rating for Haier Smart Home (600690.SH) with a current price of 25.04 CNY and a target price of 35.54 CNY [1] Core Views - The air conditioning business is significantly improving, and digital transformation is accelerating [1] - The company is expected to see a notable increase in air conditioning operations in 2025, with retail growth outpacing the industry [5] - The company continues to implement a high dividend policy, with a cash dividend ratio of 48.0% for 2024, expected to remain above 50% for 2025-2026 [7] Summary by Sections Company Overview - Haier Smart Home has appointed a new board and executive team, with key positions filled to enhance operational efficiency [5][11] - The company is focusing on digital marketing and inventory reforms to improve efficiency and brand recognition [6] Financial Performance - The company forecasts a net profit of 21.5 billion CNY for 2025, with a projected growth rate of 14.82% [10] - Revenue is expected to reach 307.31 billion CNY in 2025, reflecting a growth rate of 7.46% [10] Market Position - Haier's air conditioning retail volume has increased significantly, with online and offline sales growing by 76% and 25% respectively in early 2025 [5] - The company's market share in air conditioning has strengthened, with a year-on-year increase of 3.6% in online sales [5] Digital Transformation - The launch of Haier Smart Home AI Data Cloud has improved customer interaction and product offerings [6] - The company is replicating its successful digital strategies from the Chinese market to its overseas operations [6] Dividend and Share Buyback - The company plans to repurchase up to 10% of its H shares and 30% of its D shares, with a total buyback amount between 1 billion and 2 billion CNY [7] - The expected dividend yield for 2025 is 4.8% based on a projected net profit of 21.5 billion CNY [7]

Investment Rating - The report maintains a "Buy" rating for Haier Smart Home (600690.SH) with a current price of 25.04 CNY and a target price of 35.54 CNY [1] Core Insights - The air conditioning business is significantly improving, and digital transformation is accelerating [1] - The company is experiencing strong growth in both domestic and international markets, with a notable increase in market share [5][6] - The digital marketing and inventory reforms are enhancing operational efficiency and brand recognition [6] - The company continues to implement a high dividend policy, with a cash dividend ratio of 48.0% for 2024, expected to remain above 50% in 2025-2026 [7] Summary by Sections Financial Performance - Revenue for 2025 is projected at 307.31 billion CNY, with a growth rate of 7.46% [10] - The net profit for 2025 is estimated to be 21.52 billion CNY, reflecting a growth rate of 14.82% [10] - The expected earnings per share (EPS) for 2025 is 2.29 CNY [10] Market Position - Haier's air conditioning retail sales significantly outperformed the industry, with online and offline retail volumes increasing by 76% and 25% respectively in the first four months of 2025 [5] - The company's market share in air conditioning has strengthened, with a year-on-year increase of 3.6% in online sales and 1.0 percentage points in offline sales [5] Digital Transformation - The launch of the Haier Smart Home AI Data Cloud in Q1 2025 has improved customer interaction and product offerings [6] - The digital inventory model has reduced operational costs for clients, with over 60 new clients introduced to the POP model, resulting in a retail sales increase of over 100% [6] Management and Governance - A new board of directors and executive team has been established, with key appointments including Kevin Nolan for North America and Song Yujun for air conditioning [5][11] - The board has been authorized to repurchase up to 10% of H shares and 30% of D shares [5] Valuation and Forecast - The report maintains profit forecasts for 2025-2027 at 215 billion CNY, 243 billion CNY, and 273 billion CNY respectively, with corresponding price-to-earnings (PE) ratios of 11, 10, and 9 [7][10]

Investment Rating - The investment rating for the company is "Buy" and is maintained [7]. Core Views - On May 29, 2025, the company announced an investment of 75.075 million yuan to acquire a 20% stake in Jitai Intelligent, aiming to become the second-largest shareholder. Jitai Intelligent specializes in wall-climbing inspection robots and related operation and maintenance systems, which have certain synergies with the company's business. The target company is expected to achieve a net profit of 12.67 million yuan in 2024, and its performance is anticipated to improve significantly under the market support of the company [2][4][10]. Summary by Sections Event Description - The company plans to invest 75.075 million yuan to acquire a 20% stake in Jitai Intelligent, which will make it the second-largest shareholder [4]. Financial Performance and Forecast - Jitai Intelligent is projected to achieve revenues of 91.6537 million yuan and a net profit of 12.67 million yuan in 2024. The company expects to see a strong performance boost from the market support provided by the company [10]. - The company has a dual-driven strategy of "environmental protection + new energy," with strong order acquisition capabilities in its main business. It anticipates net profits of 1.152 billion yuan, 1.503 billion yuan, and 1.802 billion yuan for 2025, 2026, and 2027, respectively, representing year-on-year growth of 38.7%, 30.5%, and 19.9% [10].

Investment Rating - The report maintains a "Buy" rating for Haier Smart Home (600690.SH) with a current price of 25.04 CNY and a target price of 35.54 CNY [1] Core Insights - The air conditioning business is significantly improving, and digital transformation is accelerating [1] - The company has seen substantial growth in both domestic and international markets, with a notable increase in retail sales and market share in the air conditioning sector [5][6] - The digital marketing and inventory reforms have enhanced operational efficiency and brand recognition [6] - The company continues to implement a high dividend policy, with a cash dividend ratio of 48.0% for 2024, expected to remain above 50% in the coming years [7] Summary by Sections Company Overview - Haier Smart Home has appointed a new board and executive team, with key positions filled to enhance operational focus across various regions and product lines [5][11] Financial Performance - The company reported a significant increase in air conditioning retail sales, outperforming the industry average [5] - The expected net profit for 2025 is projected at 21.5 billion CNY, with a consistent growth trajectory in subsequent years [7][10] Digital Transformation - The launch of AI data cloud has improved customer interaction and product offerings, leading to successful new product launches [6] - The digital inventory model has reduced operational costs for clients, resulting in a substantial increase in retail sales through new channels [6] Dividend Policy - The company maintains a high dividend payout, with a projected dividend yield of 4.8% for 2025, supported by a robust cash flow [7][10] Valuation Metrics - The report forecasts a price-to-earnings (P/E) ratio of 11 for 2025, indicating a favorable valuation compared to historical performance [7][10][14]